Irish drug developer Amarin Corp. PLC, with research operations in Stonington, says it has wrapped all clinical studies on its remedy for lowering heart-hurting compounds in the bloodstream and is ready for its final push for regulatory clearance.
Amarin’s two Phase 3 trials for its AMR101 compound for fighting very high levels of are over and that its application for marketing approval will be submitted to federal drug regulators by the end of September.
